

Date: 16 March 2022

**Re: Freedom of Information Request**

**Ref: 74-2022**

Thank you for your email dated the 8/3/2022, requesting information in relation to multiple myeloma treatment.

The information that you require is as follows:

Could you please tell me how many patients have you treated in the last 3 months for Multiple Myeloma?  
Further, how many have received the following treatments?

**121 patients were treated in the last 3 months for multiple myeloma.**

Treatment	Patients in last 3 months
Bortezomib [Velcade] and Dexamethasone	0
Bortezomib [Velcade], Thalidomide and Dexamethasone [known as VTD]	3
Bortezomib [Velcade], Cyclophosphamide/Melphalan and Dexamethasone/Prednisolone [known as VCD or VMP]	11
Lenalidomide [Revlimid] monotherapy	48
Lenalidomide [Revlimid] and Dexamethasone	0
Lenalidomide [Revlimid], Bortezomib [Velcade] and Dexamethasone	0
Lenalidomide [Revlimid], Melphalan and Prednisolone	0
Thalidomide, Cyclophosphamide/Melphalan, and Dexamethasone/Prednisolone [known as MPT or CTD]	0
Bortezomib [Velcade] monotherapy	2
Carfilzomib [Kyprolis] and Dexamethasone	0
Carfilzomib [Kyprolis], Lenalidomide [Revlimid], and Dexamethasone [known as KRD]	0
Daratumumab [Darzalex], Velcade [Bortezomib] and Dexamethasone [known as DVD]	0
Daratumumab [Darzalex], Velcade [Bortezomib], Thalidomide and Dexamethasone [known as Dara-VTd]	0
Daratumumab [Darzalex], Lenalidomide [Revlimid] and Dexamethasone	0
Daratumumab [Darzalex], Pomalidomide [Imnovid] and Dexamethasone (DaraPd)	0
Daratumumab [Darzalex] monotherapy	32
Isatuximab [Sarclisa], Pomalidomide [Imnovid] and Dexamethasone [known as IsaPd]	5
Isatuximab [Sarclisa], Carfilzomib [Kyprolis] and Dexamethasone [known as IsaKd]	0
Ixazomib [Ninlaro], Lenalidomide [Revlimid] and Dexamethasone [known as IRD]	0

Pomalidomide [Imnovid] and Dexamethasone	0
Panobinostat [Farydak], Bortezomib [Velcade] and Dexamethasone	0
Any other systemic anti-cancer treatment	

<b>Any other systemic anti-cancer treatment</b>	<b>Patients</b>
BELANTAMAB MAFODOTIN	1
Bendamustine +Thalidomide +/- Dexam	1
Bortezomib + Daratumumab + Dex	6
CRD	1
CTD ATTENUATED(THAL 50MG)	1
CYCLO (PO)	4
Cyclophosphamide Weekly PO	4
FITNESS-IXAZOMIB	3
FITNESS-LENALIDOMIDE 10MG	1
FITNESS-LENALIDOMIDE 15MG	1
FITNESS-LENALIDOMIDE 25MG	1
Ixazomib	21
MELPHALAN IV (HIGH DOSE)	3
Melphalan oral	1
MPT	1
POMALIDOMIDE	4
PVD	4
Zoledronate	1

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

**In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:**

**<https://www.surveymonkey.co.uk/r/H39RFMM>**

Kind Regards,

Margaret Moore  
Information Governance Administrator  
Contact Email: [ccf-tr.foi@nhs.net](mailto:ccf-tr.foi@nhs.net)